Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler (NCT05620043) | Clinical Trial Compass
CompletedNot Applicable
Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler
United States21 participantsStarted 2022-09-28
Plain-language summary
To compare gene expression stimulated by a semi-permanent filler and a biostimulator via punch biopsy
Who can participate
Age range22 Years – 50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subject with a minimum of shallow nasolabial fold (NLF) contour deficiencies as assessed via the wrinkle assessment scale
* Subject with identical WAS scores on both NLFs
* Ability of giving consent for participation in the study
* Agreement to have skin biopsies on NLFs
Exclusion Criteria:
* Significant NLF asymmetry, or different WAS score on each NLF
* Pregnant, planning pregnancy during the course of the study or breastfeeding
* History of allergy or hypersensitivity to any ingredient of the treatment products
* History of allergy or hypersensitivity to anesthetics or lidocaine